{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:32Z","timestamp":1790254292212,"version":"4.1.0"},"publisher-location":"Cham","reference-count":113,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030430849","type":"print"},{"value":"9783030430856","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-43085-6_8","type":"book-chapter","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T08:03:31Z","timestamp":1596787411000},"page":"125-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Wnt Signaling in Osteosarcoma"],"prefix":"10.1007","author":[{"given":"Amit","family":"Singla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang H.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"issue":"1","key":"8_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0092-8674(82)90409-3","volume":"31","author":"R Nusse","year":"1982","unstructured":"Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31(1):99\u2013109","journal-title":"Cell"},{"issue":"1","key":"8_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X (2009) Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1):9\u201326","journal-title":"Dev Cell"},{"issue":"3","key":"8_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1297\/cpe.19.49","volume":"19","author":"T Kubota","year":"2010","unstructured":"Kubota T, Michigami T, Ozono K (2010) Wnt signaling in bone. Clin Pediatr Endocrinol 19(3):49\u201356","journal-title":"Clin Pediatr Endocrinol"},{"issue":"5","key":"8_CR4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","volume":"8","author":"TF Day","year":"2005","unstructured":"Day TF et al (2005) Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8(5):739\u2013750","journal-title":"Dev Cell"},{"issue":"5","key":"8_CR5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.devcel.2005.02.013","volume":"8","author":"TP Hill","year":"2005","unstructured":"Hill TP et al (2005) Canonical Wnt\/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8(5):727\u2013738","journal-title":"Dev Cell"},{"issue":"4","key":"8_CR6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong Y et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4):513\u2013523","journal-title":"Cell"},{"issue":"20","key":"8_CR7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM et al (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513\u20131521","journal-title":"N Engl J Med"},{"issue":"1","key":"8_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.11677","volume":"109","author":"BH Hoang","year":"2004","unstructured":"Hoang BH et al (2004) Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109(1):106\u2013111","journal-title":"Int J Cancer"},{"issue":"9","key":"8_CR9","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s11999-008-0344-y","volume":"466","author":"Y Guo","year":"2008","unstructured":"Guo Y et al (2008) Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clin Orthop Relat Res 466(9):2039\u20132045","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"8_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","volume":"17","author":"P Polakis","year":"2007","unstructured":"Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17(1):45\u201351","journal-title":"Curr Opin Genet Dev"},{"issue":"95","key":"8_CR11","doi-asserted-by":"crossref","first-page":"36780","DOI":"10.18632\/oncotarget.26377","volume":"9","author":"F Fang","year":"2018","unstructured":"Fang F et al (2018) Targeting the Wnt\/beta-catenin pathway in human osteosarcoma cells. Oncotarget 9(95):36780\u201336792","journal-title":"Oncotarget"},{"issue":"42","key":"8_CR12","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/onc.2013.443","volume":"33","author":"M Trautmann","year":"2014","unstructured":"Trautmann M et al (2014) SS18-SSX fusion protein-induced Wnt\/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 33(42):5006\u20135016","journal-title":"Oncogene"},{"issue":"5","key":"8_CR13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ccr.2011.03.010","volume":"19","author":"S Vijayakumar","year":"2011","unstructured":"Vijayakumar S et al (2011) High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF\/beta-catenin target gene, CDC25A. Cancer Cell 19(5):601\u2013612","journal-title":"Cancer Cell"},{"issue":"3","key":"8_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pbc.20124","volume":"43","author":"A Uren","year":"2004","unstructured":"Uren A et al (2004) Wnt\/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 43(3):243\u2013249","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"8_CR15","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1172\/JCI31377","volume":"117","author":"I Matushansky","year":"2007","unstructured":"Matushansky I et al (2007) Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 117(11):3248\u20133257","journal-title":"J Clin Invest"},{"issue":"16","key":"8_CR16","doi-asserted-by":"crossref","first-page":"21114","DOI":"10.18632\/oncotarget.8522","volume":"7","author":"SD Goldstein","year":"2016","unstructured":"Goldstein SD et al (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7(16):21114\u201321123","journal-title":"Oncotarget"},{"issue":"30","key":"8_CR17","doi-asserted-by":"crossref","first-page":"28067","DOI":"10.1074\/jbc.M300373200","volume":"278","author":"CA Gregory","year":"2003","unstructured":"Gregory CA et al (2003) The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 278(30):28067\u201328078","journal-title":"J Biol Chem"},{"issue":"1","key":"8_CR18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/path.2628","volume":"220","author":"Y Cai","year":"2010","unstructured":"Cai Y et al (2010) Inactive Wnt\/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 220(1):24\u201333","journal-title":"J Pathol"},{"issue":"12","key":"8_CR19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.biocel.2012.08.022","volume":"44","author":"Z Yu","year":"2012","unstructured":"Yu Z et al (2012) Cancer stem cells. Int J Biochem Cell Biol 44(12):2144\u20132151","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"8_CR20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcp.25179","volume":"231","author":"SR Martins-Neves","year":"2016","unstructured":"Martins-Neves SR et al (2016) Osteosarcoma stem cells have active Wnt\/beta-catenin and Overexpress SOX2 and KLF4. J Cell Physiol 231(4):876\u2013886","journal-title":"J Cell Physiol"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.11.004","volume":"414","author":"SR Martins-Neves","year":"2018","unstructured":"Martins-Neves SR et al (2018) IWR-1, a tankyrase inhibitor, attenuates Wnt\/beta-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett 414:1\u201315","journal-title":"Cancer Lett"},{"issue":"24","key":"8_CR22","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2000.18.24.4016","volume":"18","author":"G Bacci","year":"2000","unstructured":"Bacci G et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli\/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18(24):4016\u20134027","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR23","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cncr.21263","volume":"104","author":"V Mialou","year":"2005","unstructured":"Mialou V et al (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 104(5):1100\u20131109","journal-title":"Cancer"},{"issue":"2","key":"8_CR24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jnci\/djk015","volume":"99","author":"IJ Lewis","year":"2007","unstructured":"Lewis IJ et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2):112\u2013128","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"8_CR25","doi-asserted-by":"crossref","first-page":"a011163","DOI":"10.1101\/cshperspect.a011163","volume":"4","author":"R Nusse","year":"2012","unstructured":"Nusse R (2012) Wnt signaling. Cold Spring Harb Perspect Biol 4(5):a011163","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"8_CR26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.biocel.2012.03.001","volume":"44","author":"C Jamieson","year":"2012","unstructured":"Jamieson C, Sharma M, Henderson BR (2012) Wnt signaling from membrane to nucleus: beta-catenin caught in a loop. Int J Biochem Cell Biol 44(6):847\u2013850","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"8_CR27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.CR0070024","volume":"104","author":"F Takahashi-Yanaga","year":"2007","unstructured":"Takahashi-Yanaga F, Sasaguri T (2007) The Wnt\/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 104(4):293\u2013302","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"8_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00432-003-0431-0","volume":"129","author":"B Lustig","year":"2003","unstructured":"Lustig B, Behrens J (2003) The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129(4):199\u2013221","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"8_CR29","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1172\/JCI84658","volume":"126","author":"H Kimura","year":"2016","unstructured":"Kimura H et al (2016) CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J Clin Invest 126(7):2689\u20132705","journal-title":"J Clin Invest"},{"issue":"4","key":"8_CR30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/bdrc.20195","volume":"90","author":"R Sugimura","year":"2010","unstructured":"Sugimura R, Li L (2010) Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res C Embryo Today 90(4):243\u2013256","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"2","key":"8_CR31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.abb.2008.03.006","volume":"473","author":"E Piters","year":"2008","unstructured":"Piters E, Boudin E, Van Hul W (2008) Wnt signaling: a win for bone. Arch Biochem Biophys 473(2):112\u2013116","journal-title":"Arch Biochem Biophys"},{"issue":"7","key":"8_CR32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jor.20356","volume":"25","author":"Y Guo","year":"2007","unstructured":"Guo Y et al (2007) Blocking Wnt\/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 25(7):964\u2013971","journal-title":"J Orthop Res"},{"issue":"19","key":"8_CR33","doi-asserted-by":"crossref","first-page":"17570","DOI":"10.18632\/oncotarget.4100","volume":"6","author":"C Chen","year":"2015","unstructured":"Chen C et al (2015) Aberrant activation of Wnt\/beta-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 6(19):17570\u201317583","journal-title":"Oncotarget"},{"issue":"2","key":"8_CR34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.canlet.2015.11.013","volume":"370","author":"SR Martins-Neves","year":"2016","unstructured":"Martins-Neves SR et al (2016) Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt\/beta-catenin signaling. Cancer Lett 370(2):286\u2013295","journal-title":"Cancer Lett"},{"issue":"11","key":"8_CR35","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/sj.bjc.6604069","volume":"97","author":"N Lee","year":"2007","unstructured":"Lee N et al (2007) A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97(11):1552\u20131559","journal-title":"Br J Cancer"},{"key":"8_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.67","volume":"5","author":"U Krause","year":"2014","unstructured":"Krause U et al (2014) An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity. Cell Death Dis 5:e1093","journal-title":"Cell Death Dis"},{"issue":"36","key":"8_CR37","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/onc.2009.175","volume":"28","author":"M Enomoto","year":"2009","unstructured":"Enomoto M et al (2009) Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a\/Ror2 signaling. Oncogene 28(36):3197\u20133208","journal-title":"Oncogene"},{"issue":"2","key":"8_CR38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/path.1449","volume":"201","author":"C Wissmann","year":"2003","unstructured":"Wissmann C et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2):204\u2013212","journal-title":"J Pathol"},{"issue":"3","key":"8_CR39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/1535-7163.MCT-09-0147","volume":"9","author":"EM Rubin","year":"2010","unstructured":"Rubin EM et al (2010) Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9(3):731\u2013741","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"8_CR40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgi379","volume":"27","author":"L Ai","year":"2006","unstructured":"Ai L et al (2006) Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27(7):1341\u20131348","journal-title":"Carcinogenesis"},{"issue":"14","key":"8_CR41","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/0008-5472.CAN-04-1389","volume":"64","author":"J Mazieres","year":"2004","unstructured":"Mazieres J et al (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14):4717\u20134720","journal-title":"Cancer Res"},{"issue":"53","key":"8_CR42","doi-asserted-by":"crossref","first-page":"7946","DOI":"10.1038\/sj.onc.1208910","volume":"24","author":"H Taniguchi","year":"2005","unstructured":"Taniguchi H et al (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53):7946\u20137952","journal-title":"Oncogene"},{"issue":"19","key":"8_CR43","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-09-0111","volume":"15","author":"BB Lee","year":"2009","unstructured":"Lee BB et al (2009) Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15(19):6185\u20136191","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8_CR44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI37175","volume":"119","author":"M Kansara","year":"2009","unstructured":"Kansara M et al (2009) Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119(4):837\u2013851","journal-title":"J Clin Invest"},{"issue":"42","key":"8_CR45","doi-asserted-by":"crossref","first-page":"26131","DOI":"10.1074\/jbc.271.42.26131","volume":"271","author":"B Hoang","year":"1996","unstructured":"Hoang B et al (1996) Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem 271(42):26131\u201326137","journal-title":"J Biol Chem"},{"issue":"6","key":"8_CR46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0092-8674(00)81921-2","volume":"88","author":"L Leyns","year":"1997","unstructured":"Leyns L et al (1997) Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88(6):747\u2013756","journal-title":"Cell"},{"key":"8_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2018.06.059","volume":"674","author":"D Bravo","year":"2018","unstructured":"Bravo D et al (2018) Decreased local and systemic levels of sFRP3 protein in osteosarcoma patients. Gene 674:1\u20137","journal-title":"Gene"},{"issue":"5","key":"8_CR48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.devcel.2011.09.003","volume":"21","author":"VE Ahn","year":"2011","unstructured":"Ahn VE et al (2011) Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5\/6. Dev Cell 21(5):862\u2013873","journal-title":"Dev Cell"},{"issue":"1","key":"8_CR49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi S et al (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165(1):45\u201360","journal-title":"Cell"},{"issue":"29","key":"8_CR50","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/sj.onc.1209439","volume":"25","author":"O Aguilera","year":"2006","unstructured":"Aguilera O et al (2006) Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25(29):4116\u20134121","journal-title":"Oncogene"},{"issue":"8","key":"8_CR51","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/ijc.25507","volume":"128","author":"H Hirata","year":"2011","unstructured":"Hirata H et al (2011) Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 128(8):1793\u20131803","journal-title":"Int J Cancer"},{"issue":"1","key":"8_CR52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/carcin\/bgg190","volume":"25","author":"AM Mikheev","year":"2004","unstructured":"Mikheev AM et al (2004) A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 25(1):47\u201359","journal-title":"Carcinogenesis"},{"issue":"4","key":"8_CR53","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1349-7006.2012.02222.x","volume":"103","author":"L Qi","year":"2012","unstructured":"Qi L et al (2012) Dickkopf-1 inhibits epithelial-mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Sci 103(4):828\u2013835","journal-title":"Cancer Sci"},{"issue":"8","key":"8_CR54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/0960327113510537","volume":"33","author":"H Begenik","year":"2014","unstructured":"Begenik H et al (2014) The association between serum Dickkopf-1 levels and esophageal squamous cell carcinoma. Hum Exp Toxicol 33(8):785\u2013788","journal-title":"Hum Exp Toxicol"},{"issue":"117","key":"8_CR55","first-page":"1661","volume":"59","author":"I Gomceli","year":"2012","unstructured":"Gomceli I et al (2012) A novel screening biomarker in gastric cancer: serum Dickkopf-1. Hepato-Gastroenterology 59(117):1661\u20131664","journal-title":"Hepato-Gastroenterology"},{"issue":"13","key":"8_CR56","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/pros.20805","volume":"68","author":"CL Hall","year":"2008","unstructured":"Hall CL et al (2008) Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68(13):1396\u20131404","journal-title":"Prostate"},{"issue":"17","key":"8_CR57","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1080\/15384101.2017.1356510","volume":"16","author":"DJ Liu","year":"2017","unstructured":"Liu DJ et al (2017) The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Cell Cycle 16(17):1622\u20131629","journal-title":"Cell Cycle"},{"issue":"7","key":"8_CR58","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/cam4.702","volume":"5","author":"YH Peng","year":"2016","unstructured":"Peng YH et al (2016) Combined detection of serum Dickkopf-1 and its autoantibodies to diagnose esophageal squamous cell carcinoma. Cancer Med 5(7):1388\u20131396","journal-title":"Cancer Med"},{"key":"8_CR59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/1471-2407-14-649","volume":"14","author":"TD Rachner","year":"2014","unstructured":"Rachner TD et al (2014) High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer 14:649","journal-title":"BMC Cancer"},{"issue":"2","key":"8_CR60","first-page":"OC32","volume":"11","author":"M Watany","year":"2017","unstructured":"Watany M et al (2017) Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J Clin Diagn Res 11(2):OC32\u2013OC34","journal-title":"J Clin Diagn Res"},{"key":"8_CR61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-4598-12-157","volume":"12","author":"L Chen","year":"2013","unstructured":"Chen L et al (2013) DKK1 promotes hepatocellular carcinoma cell migration and invasion through beta-catenin\/MMP7 signaling pathway. Mol Cancer 12:157","journal-title":"Mol Cancer"},{"issue":"2","key":"8_CR62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M et al (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2):371\u2013379","journal-title":"Blood"},{"issue":"7","key":"8_CR63","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1245\/s10434-009-0476-7","volume":"16","author":"T Makino","year":"2009","unstructured":"Makino T et al (2009) Dickkopf-1 expression as a marker for predicting clinical outcome in esophageal squamous cell carcinoma. Ann Surg Oncol 16(7):2058\u20132064","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"8_CR64","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ncb3613","volume":"19","author":"X Zhuang","year":"2017","unstructured":"Zhuang X et al (2017) Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol 19(10):1274\u20131285","journal-title":"Nat Cell Biol"},{"issue":"1","key":"8_CR65","first-page":"18","volume":"1825","author":"J Veeck","year":"2012","unstructured":"Veeck J, Dahl E (2012) Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta 1825(1):18\u201328","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"8_CR66","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/0008-5472.CAN-03-1952","volume":"64","author":"BH Hoang","year":"2004","unstructured":"Hoang BH et al (2004) Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64(8):2734\u20132739","journal-title":"Cancer Res"},{"key":"8_CR67","first-page":"147541","volume":"2013","author":"CH Lin","year":"2013","unstructured":"Lin CH et al (2013) Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013:147541","journal-title":"Sarcoma"},{"issue":"20","key":"8_CR68","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X et al (2005) Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem 280(20):19883\u201319887","journal-title":"J Biol Chem"},{"issue":"32","key":"8_CR69","doi-asserted-by":"crossref","first-page":"26464","DOI":"10.1074\/jbc.M112.350108","volume":"287","author":"G Holdsworth","year":"2012","unstructured":"Holdsworth G et al (2012) Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. J Biol Chem 287(32):26464\u201326477","journal-title":"J Biol Chem"},{"issue":"3","key":"8_CR70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","volume":"78","author":"BL Clarke","year":"2014","unstructured":"Clarke BL (2014) Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas 78(3):199\u2013204","journal-title":"Maturitas"},{"issue":"1","key":"8_CR71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/14712598.2011.540565","volume":"11","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. Expert Opin Biol Ther 11(1):117\u2013127","journal-title":"Expert Opin Biol Ther"},{"issue":"5\u20136","key":"8_CR72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1759720X18775936","volume":"10","author":"ASK Solling","year":"2018","unstructured":"Solling ASK, Harslof T, Langdahl B (2018) The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 10(5\u20136):105\u2013115","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"15","key":"8_CR73","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"6","key":"8_CR74","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00223-016-0231-6","volume":"100","author":"J Zou","year":"2017","unstructured":"Zou J, Zhang W, Li XL (2017) Effects of SOST gene silencing on proliferation, apoptosis, invasion, and migration of human osteosarcoma cells through the Wnt\/beta-catenin signaling pathway. Calcif Tissue Int 100(6):551\u2013564","journal-title":"Calcif Tissue Int"},{"issue":"13","key":"8_CR75","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/j.febslet.2005.04.013","volume":"579","author":"CH Park","year":"2005","unstructured":"Park CH et al (2005) The inhibitory mechanism of curcumin and its derivative against beta-catenin\/Tcf signaling. FEBS Lett 579(13):2965\u20132971","journal-title":"FEBS Lett"},{"issue":"3","key":"8_CR76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033976","volume":"7","author":"RM Hallett","year":"2012","unstructured":"Hallett RM et al (2012) Small molecule antagonists of the Wnt\/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2\/Neu mouse model of breast cancer. PLoS One 7(3):e33976","journal-title":"PLoS One"},{"issue":"6","key":"8_CR77","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s10637-009-9311-z","volume":"28","author":"PC Leow","year":"2010","unstructured":"Leow PC et al (2010) Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt\/beta-catenin antagonists against human osteosarcoma cells. Investig New Drugs 28(6):766\u2013782","journal-title":"Investig New Drugs"},{"issue":"5","key":"8_CR78","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.3892\/mmr.2015.4338","volume":"12","author":"Y Zou","year":"2015","unstructured":"Zou Y, Yang J, Jiang D (2015) Resveratrol inhibits canonical Wnt signaling in human MG-63 osteosarcoma cells. Mol Med Rep 12(5):7221\u20137226","journal-title":"Mol Med Rep"},{"issue":"2","key":"8_CR79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nchembio.137","volume":"5","author":"B Chen","year":"2009","unstructured":"Chen B et al (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5(2):100\u2013107","journal-title":"Nat Chem Biol"},{"issue":"12","key":"8_CR80","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/ml4003315","volume":"4","author":"H Huang","year":"2013","unstructured":"Huang H et al (2013) Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors. ACS Med Chem Lett 4(12):1218\u20131223","journal-title":"ACS Med Chem Lett"},{"issue":"28","key":"8_CR81","doi-asserted-by":"crossref","first-page":"25390","DOI":"10.18632\/oncotarget.4455","volume":"6","author":"L Ma","year":"2015","unstructured":"Ma L et al (2015) Tankyrase inhibitors attenuate WNT\/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget 6(28):25390\u201325401","journal-title":"Oncotarget"},{"issue":"12","key":"8_CR82","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1111\/cas.13805","volume":"109","author":"A Mizutani","year":"2018","unstructured":"Mizutani A et al (2018) RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci 109(12):4003\u20134014","journal-title":"Cancer Sci"},{"issue":"1","key":"8_CR83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cam4.170","volume":"3","author":"EW Stratford","year":"2014","unstructured":"Stratford EW et al (2014) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med 3(1):36\u201346","journal-title":"Cancer Med"},{"key":"8_CR84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fphar.2017.00285","volume":"8","author":"CT Gustafson","year":"2017","unstructured":"Gustafson CT et al (2017) FH535 suppresses osteosarcoma growth in vitro and inhibits Wnt signaling through tankyrases. Front Pharmacol 8:285","journal-title":"Front Pharmacol"},{"issue":"24","key":"8_CR85","doi-asserted-by":"crossref","first-page":"16256","DOI":"10.1074\/jbc.M109.009647","volume":"284","author":"D Grandy","year":"2009","unstructured":"Grandy D et al (2009) Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284(24):16256\u201316263","journal-title":"J Biol Chem"},{"issue":"11","key":"8_CR86","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/jnci\/djz026","volume":"111","author":"M Nomura","year":"2019","unstructured":"Nomura M et al (2019) Tegavivint and the beta-catenin\/ALDH Axis in chemotherapy-resistant and metastatic osteosarcoma. J Natl Cancer Inst 111(11):1216\u20131227","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"8_CR87","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3892\/or.2015.3766","volume":"33","author":"Z Li","year":"2015","unstructured":"Li Z et al (2015) Niclosamide inhibits the proliferation of human osteosarcoma cell lines by inducing apoptosis and cell cycle arrest. Oncol Rep 33(4):1763\u20131768","journal-title":"Oncol Rep"},{"issue":"8","key":"8_CR88","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/1568009615666150629132157","volume":"15","author":"Z Liao","year":"2015","unstructured":"Liao Z et al (2015) The anthelmintic drug niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways. Curr Cancer Drug Targets 15(8):726\u2013738","journal-title":"Curr Cancer Drug Targets"},{"issue":"27","key":"8_CR89","doi-asserted-by":"crossref","first-page":"42126","DOI":"10.18632\/oncotarget.9704","volume":"7","author":"L Yin","year":"2016","unstructured":"Yin L et al (2016) Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt\/beta-catenin signaling. Oncotarget 7(27):42126\u201342138","journal-title":"Oncotarget"},{"issue":"12","key":"8_CR90","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nrd2154","volume":"5","author":"N Barker","year":"2006","unstructured":"Barker N, Clevers H (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5(12):997\u20131014","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"8_CR91","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg1427","volume":"5","author":"RT Moon","year":"2004","unstructured":"Moon RT et al (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5(9):691\u2013701","journal-title":"Nat Rev Genet"},{"issue":"2","key":"8_CR92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/labinvest.3700509","volume":"87","author":"J Luo","year":"2007","unstructured":"Luo J et al (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Investig 87(2):97\u2013103","journal-title":"Lab Investig"},{"key":"8_CR93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1476-4598-8-76","volume":"8","author":"W Wei","year":"2009","unstructured":"Wei W et al (2009) Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 8:76","journal-title":"Mol Cancer"},{"issue":"15","key":"8_CR94","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1158\/0008-5472.CAN-04-1227","volume":"64","author":"L You","year":"2004","unstructured":"You L et al (2004) An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64(15):5385\u20135389","journal-title":"Cancer Res"},{"issue":"6","key":"8_CR95","first-page":"1671","volume":"60","author":"IM Shih","year":"2000","unstructured":"Shih IM et al (2000) The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 60(6):1671\u20131676","journal-title":"Cancer Res"},{"issue":"9","key":"8_CR96","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/0008-5472.CAN-05-4422","volume":"66","author":"S Patane","year":"2006","unstructured":"Patane S et al (2006) MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66(9):4750\u20134757","journal-title":"Cancer Res"},{"issue":"4","key":"8_CR97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252\u2013266","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"8_CR98","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/147323001003800411","volume":"38","author":"JJ Xia","year":"2010","unstructured":"Xia JJ et al (2010) Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res 38(4):1294\u20131304","journal-title":"J Int Med Res"},{"issue":"6","key":"8_CR99","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1101\/gad.233627.113","volume":"28","author":"J Juan","year":"2014","unstructured":"Juan J et al (2014) Diminished WNT -> beta-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 28(6):561\u2013575","journal-title":"Genes Dev"},{"issue":"10","key":"8_CR100","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1634\/stemcells.2005-0034","volume":"23","author":"G Dravid","year":"2005","unstructured":"Dravid G et al (2005) Defining the role of Wnt\/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells. Stem Cells 23(10):1489\u20131501","journal-title":"Stem Cells"},{"issue":"6","key":"8_CR101","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R (2012) Wnt\/beta-catenin signaling and disease. Cell 149(6):1192\u20131205","journal-title":"Cell"},{"issue":"6","key":"8_CR102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0092-8674(04)00255-7","volume":"116","author":"E Fuchs","year":"2004","unstructured":"Fuchs E, Tumbar T, Guasch G (2004) Socializing with the neighbors: stem cells and their niche. Cell 116(6):769\u2013778","journal-title":"Cell"},{"issue":"4","key":"8_CR103","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/BCO.0b013e318221aee8","volume":"22","author":"CP Gibbs Jr","year":"2011","unstructured":"Gibbs CP Jr, Levings PP, Ghivizzani SC (2011) Evidence for the osteosarcoma stem cell. Curr Orthop Pract 22(4):322\u2013326","journal-title":"Curr Orthop Pract"},{"issue":"11","key":"8_CR104","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1593\/neo.05394","volume":"7","author":"CP Gibbs","year":"2005","unstructured":"Gibbs CP et al (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7(11):967\u2013976","journal-title":"Neoplasia"},{"issue":"10","key":"8_CR105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003469","volume":"3","author":"V Tirino","year":"2008","unstructured":"Tirino V et al (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3(10):e3469","journal-title":"PLoS One"},{"issue":"2","key":"8_CR106","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ijc.25331","volume":"128","author":"L Wang","year":"2011","unstructured":"Wang L et al (2011) Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128(2):294\u2013303","journal-title":"Int J Cancer"},{"key":"8_CR107","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2407-12-139","volume":"12","author":"SR Martins-Neves","year":"2012","unstructured":"Martins-Neves SR et al (2012) Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 12:139","journal-title":"BMC Cancer"},{"issue":"10","key":"8_CR108","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/jcb.24850","volume":"115","author":"W Lu","year":"2014","unstructured":"Lu W, Li Y (2014) Salinomycin suppresses LRP6 expression and inhibits both Wnt\/beta-catenin and mTORC1 signaling in breast and prostate cancer cells. J Cell Biochem 115(10):1799\u20131807","journal-title":"J Cell Biochem"},{"issue":"17","key":"8_CR109","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/bph.14770","volume":"176","author":"Z Wang","year":"2019","unstructured":"Wang Z et al (2019) Salinomycin exerts anti-colorectal cancer activity by targeting the beta-catenin\/TCF complex. Br J Pharmacol 176(17):3390\u20133406","journal-title":"Br J Pharmacol"},{"issue":"1","key":"8_CR110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2011.07.016","volume":"311","author":"QL Tang","year":"2011","unstructured":"Tang QL et al (2011) Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 311(1):113\u2013121","journal-title":"Cancer Lett"},{"key":"8_CR111","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/nnm.15.73","volume":"10","author":"M Ni","year":"2015","unstructured":"Ni M et al (2015) Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells. Int J Nanomedicine 10:2537\u20132554","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"8_CR112","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.nano.2018.05.015","volume":"14","author":"F Chen","year":"2018","unstructured":"Chen F et al (2018) Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine 14(7):2115\u20132127","journal-title":"Nanomedicine"},{"issue":"39","key":"8_CR113","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/onc.2014.429","volume":"34","author":"S Zhao","year":"2015","unstructured":"Zhao S et al (2015) NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene 34(39):5069\u20135079","journal-title":"Oncogene"}],"container-title":["Advances in Experimental Medicine and Biology","Current Advances in the Science of Osteosarcoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-43085-6_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T23:13:38Z","timestamp":1616886818000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-43085-6_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030430849","9783030430856"],"references-count":113,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-43085-6_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"8 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}